Hitgen

S55746 is a Novel Orally Active BCL-2 Selective and Potent Inhibitor That Impairs Haematological Tumour Growth

S55746 is a Novel Orally Active BCL-2 Selective and Potent Inhibitor That Impairs Haematological Tumour Growth

Casara, P. et al., Oncotarget 2018, 9, 20075–20088

< Back to all news
Would you like to learn more?

For further information about partnering with Vernalis, or to find out more about our capabilities or career opportunities.

bd@vernalis.com hr@vernalis.com
Contact us

Services

© 2024 Vernalis (R&D) Limited. All Rights Reserved. Web Design by Red Graphic. Web Development by Red Web.